Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million USD through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.Through the deal, Regeneron says it aims to bolster its capabilities in genomics-driven drug
This content is restricted.